Shaik, M. Naveed
Pfizer (United States)
4 papers on CoChatORCID 0000-0002-2862-7089
Most cited papers
- Verified
Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
Flaherty, K. T., LoRusso, P. M., DeMichele, A., Abramson, V. G., Courtney, R., Randolph, S. S., Shaik, M. N., Wilner, K. D., O'Dwyer, P. J., & Schwartz, G. K. (2012) · Clinical Cancer Research
Advanced Breast Cancer TherapiesCancer-related Molecular Pathways
Cited by 366
- Verified
Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)
Schwartz, G. K., LoRusso, P. M., Dickson, M. A., Randolph, S. S., Shaik, M. N., Wilner, K. D., Courtney, R., & O'Dwyer, P. J. (2011) · British Journal of Cancer
Advanced Breast Cancer TherapiesCancer-related Molecular Pathways
Cited by 260
- Verified
A Phase I, Dose-Finding Study in Patients with Advanced Solid Malignancies of the Oral γ-Secretase Inhibitor PF-03084014
Messersmith, W. A., Shapiro, G. I., Cleary, J. M., Jimeno, A., Dasari, A., Huang, B., Shaik, M. N., Cesari, R., Zheng, X., Reynolds, J. M., et al. (2015) · Clinical Cancer Research
Alzheimer's disease research and treatmentsWnt/β-catenin signaling in development and cancer
Cited by 218
- Verified
A Phase 1 study of the novel gamma‐secretase inhibitor PF‐03084014 in patients with T‐cell acute lymphoblastic leukemia and T‐cell lymphoblastic lymphoma
Papayannidis, C., DeAngelo, D. J., Stock, W., Huang, B., Shaik, M. N., Cesari, R., Zheng, X., Reynolds, J. M., English, P. A., Ozeck, M., et al. (2015) · Blood Cancer Journal
Acute Lymphoblastic Leukemia researchChronic Lymphocytic Leukemia Research
Cited by 122
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free